Targeting mitochondrial ROS in the liver-brain axis attenuates inflammation and oxidative stress in covert hepatic...

Area of Science:

• Hepatology
• Neuroscience
• Mitochondrial Medicine

Background:

• Covert hepatic encephalopathy (CHE) is a serious complication of chronic liver disease.
• Hyperammonemia and oxidative stress are key factors in CHE pathogenesis.
• Mitochondria-targeted antioxidants may help, but their role in CHE needs more study.

Purpose of the Study:

• To investigate the efficacy of the mitochondria-targeted antioxidant MitoQ in CHE.
• To explore MitoQ's effects on oxidative stress, inflammation, and organ function in CHE.
• To understand the liver-brain axis in CHE and potential therapeutic strategies.

Main Methods:

• Analysis of clinical samples from cirrhotic patients with hyperammonemia.
• In vitro studies using neuronal cells exposed to ammonia.
• In vivo studies using a bile duct ligation mouse model of CHE.
• Assessment of oxidative stress markers, mitochondrial function, hepatic injury, fibrosis, inflammation, and neurological function.

Main Results:

• Cirrhotic patients showed dysregulated peripheral oxidative stress markers.
• MitoQ attenuated ammonia-induced mitochondrial dysfunction in neuronal cells.
• MitoQ administration in a mouse model reduced liver injury, fibrosis, and multi-organ oxidative stress and inflammation.
• MitoQ improved motor coordination and metabolic stability in CHE mice.

Conclusions:

• MitoQ demonstrates multi-organ protective effects by targeting mitochondrial ROS along the liver-brain axis.
• MitoQ restores redox homeostasis and suppresses inflammation, offering a novel therapeutic strategy for CHE.
• This study provides preclinical evidence for mitochondrial-targeted antioxidants in managing hepatic encephalopathy.